This rarest element on Earth could cure cancer, but here’s the catch

Astatine-211 (At-211) is an isotope gaining significant attention in medical research, potentially offering a revolution in how cancer is treated. It is known as the rarest naturally occurring element on Earth and remains one of the least understood elements on the periodic table. Although its very name, derived from Greek, means "unstable," this fleeting element is now being hailed as a highly precise tool for targeted cancer therapy

What makes Astatine-211 the 'Goldilocks' isotope?

Astatine is the rarest naturally occurring element on Earth and remains one of the least explored entries on the periodic table. Its Greek name accurately translates to "unstable," meaning it exists only fleetingly in nature. Despite its instability and short 7.2-hour half-life, the isotope Astatine-211 (At-211) shows remarkable promise in targeted cancer treatment.

At-211 is often referred to as the "perfect" or "Goldilocks" isotope. This description stems from its ability to deliver precisely the necessary amount of radiation to destroy malignant cells while keeping the surrounding tissue unharmed.

This breakthrough isotope has demonstrated strong potential in treating blood cancers, ovarian tumours, and certain brain cancers.

The Director of the Cyclotron Institute, Dr. Sherry J Yennello, who is also a Distinguished Professor and Regents Professor of Chemistry at Texas A&M, noted that targeted alpha therapy is a potentially transformative cancer treatment that draws great interest because it causes large amounts of damage near a tumour cell while maintaining the integrity of the healthy surrounding tissue and organs.

How does Astatine precisely attack tumours?

Astatine works by emitting alpha particles when it decays. Alpha particles are tiny clusters composed of two protons and two neutrons. These particles release powerful, localised bursts of energy that are highly effective at destroying cancer cells. Crucially, alpha particles travel only a short distance before releasing their energy.

This characteristic minimises the damage inflicted upon healthy tissue. When At-211 is carefully positioned near or within tumours, its alpha emissions penetrate just deep enough to eliminate the cancerous cells while ensuring surrounding organs are spared.

Furthermore, At-211's short half-life ensures it rapidly loses its radioactivity, making it less toxic compared to radiopharmaceuticals that remain active for longer periods. Unlike many other isotopes used in treatment, At-211 does not produce harmful secondary alpha decay, guaranteeing that its energy is used efficiently for the therapy.

This combination of safety and precision has captured the attention of researchers and pharmaceutical developers across the globe. At-211 is currently being tested in clinical trials for blood cancers and is also being explored for potential applications in treating Alzheimer's disease.

How are scientists producing and shipping this rare element?

Harnessing At-211’s potential requires overcoming significant production challenges. Dr. Yennello explained that the biggest obstacle to using Astatine-211 to transform the future of nuclear medicine is its availability.

She expressed optimism that the advances being made at Texas A&M will significantly help in addressing this issue. Scientists at Texas A&M University have employed cyclotron beams and advanced chemical techniques to develop a method for producing, isolating, and shipping Astatine-211. The production process involves using the K150 cyclotron within the Texas A&M Cyclotron Institute. This effort is supported by the US Department of Energy (DOE) Isotope Program.

Since 2023, Texas A&M has stood as one of only two national suppliers of astatine for targeted cancer therapy, operating through the National Isotope Development Center (NIDC) and its University Isotope Network.

Dr. Yennello confirmed that Texas A&M is one of a handful of US centres capable of routinely producing astatine in medically relevant quantities and delivering it to nearby facilities. One of the greatest achievements by Texas A&M has been the creation of an automated system designed for separating and shipping At-211.

This technology, which is currently patent-pending, purifies the isotope by removing it from the bismuth target and then loads it onto a shipping column so it can be incorporated into targeted alpha therapy drugs. The new resin-column trapping technique allows for quicker processing.

This speed ensures that larger quantities of At-211 can be shipped with minimal decay and reduced risk compared with older, traditional methods. This production improvement substantially strengthens the case for At-211 as a viable next-generation cancer treatment.

What collaborations are advancing global research?

Texas A&M has already supplied significant batches of At-211 to collaborating partners, including MD Anderson Cancer Center, which has received more than two dozen shipments, and the University of Alabama at Birmingham.

These key partnerships are instrumental in helping researchers refine radiopharmaceuticals based on At-211 and deepen their comprehension of the element's chemical behaviour. The growing international interest in At-211 research was recently highlighted by Dr. Yennello at the 26th International Symposium on Radiopharmaceutical Sciences, held in Queensland.

Dr. Yennello mentioned that although clinical trials involving humans are still in the early stages, initiatives are currently investigating astatine-211’s potential in the United States, Japan, and several European countries.

She stated she was looking forward to sharing Texas A&M’s success in producing and supplying astatine-211 while simultaneously learning about global progress in the collective efforts to better understand its chemical properties and potential therapeutic advancement in oncology.

Dr. Yennello and Dr. Federica Pisaneschi, a former MD Anderson radiochemist now affiliated with the University of Texas Health Science Center at Houston, are scheduled to present their findings at the 2025 World Astatine Community Meeting in New Orleans.

Their talk, entitled "The Texas Two-Step," will showcase their shared experience in producing, shipping, and applying At-211 for therapeutic use. This meeting, the first of its kind to be held in the US, will unite commercial groups and researchers dedicated to expanding the role of At-211 in cancer treatment globally.